US Patent

US12552792 — Solid forms of an FGFR inhibitor and processes for preparing the same

Composition of Matter · Assigned to Incyte Corp · Expires 2040-10-03 · 14y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects solid forms and methods of preparation for a specific FGFR inhibitor molecule, useful in treating FGFR-associated diseases like cancer.

USPTO Abstract

The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US12552792
Jurisdiction
US
Classification
Composition of Matter
Expires
2040-10-03
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.